Something needs to be done. This will be a $100 M sales company in 2013. They do need a second product and expand on current label, but, Cubist? Bayer? can look at this in 2013 and snap it up.
Regarding Cubist ... the $2.8 billion company, with at least three new therapies in the pipeline, still will need to use its $897 million in cash to buy a drugmaker such as Optimer Pharmaceuticals Inc. or Cadence Pharmaceuticals Inc., said Robert W. Baird & Co. A takeover of either would top Cubist’s largest deals for Calixa Therapeutics Inc. and Adolor Corp., data compiled by Bloomberg show. Cantor Fitzgerald LP says it also could look to smaller targets Trius Therapeutics Inc. or Cempra Inc. to add to its antibiotics portfolio.